Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Plasma cell 1Lymphoid 1CNS 1Breast 1

Conditions

Breast Neoplasms 75HER2-positive Breast Cancer 10Neoplasms 8Neoplasm Metastasis 4Colonic Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Endometrial Neoplasms 3Brain Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2HER2-positive Early Breast Cancer 2Colorectal Neoplasms 2Breast Diseases 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1

Interventions

Gemcitabine 56pembrolizumab 51Cisplatin 43Magnetic Resonance Spectroscopy 27enfortumab vedotin 23Specimen Handling 22Nivolumab 22Cystectomy 18durvalumab 16Carboplatin 16avelumab 14Mitomycin 14atezolizumab 13Docetaxel 13Cystoscopy 12Fluorouracil 11Radiation 9Transurethral Resection of Bladder 8Radiotherapy 8Ipilimumab 8sacituzumab govitecan 7Standard of Care 7Radiosurgery 7Paclitaxel 7Immunoglobulin G 7Disulfides 7erdafitinib 6cemiplimab 6Surveys and Questionnaires 6Surgical Procedures, Operative 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × pertuzumab × 1 year × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05786716 2025-12-02

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡